Abstract
There are currently seven metastatic renal cell carcinoma treatment options. In the first line therapy we standardly use sunitinib, pazopanib, bevacizumab with interferon alpha and sorafenib.
We can treat with everolimus, axitinib or sorafenib after the first line therapy failure. Aging of the population is a phenomenon emerging in the developing countries, so we meet the elderly patients more often.
These elderly patients may have many comorbidities and they often use non oncological treatments. On the other hand the calendar age does not correspond to the biological age so it should not be an obstacle to treatment with targeted therapy.
The main goal of this article is a short review concerning targeted therapy for elderly patients with metastatic renal cell carcinoma.